Total Funding
74
2
Total FundingPost-IPO Equity raised
Growth Score
-9 pts
Heat Score
-5 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
3953196
Alseres Pharmaceuticals, Inc. (ALSE) is focused on the development of diagnostic and therapeutic products for disorders in the central
- Kenneth Rice: CFO
About the Company
Alseres Pharmaceuticals, Inc. (ALSE) is focused on the development of diagnostic and therapeutic products for disorders in the central nervous system (CNS). Our lead product candidate is Altropane®, a proprietary molecular imaging agent used to diagnose Parkinson's disease and dementia. Altropane is presently in Phase III clinical development
for the diagnosis of Parkinson's disease. Our development strategy for Altropane anticipates entering into one or more partnerships to ensure development and commercialization of the product.
